Anthera Provides Clinical Program Updates for Blisibimod and Sollpura® (Anthera Pharmaceuticals Inc)

(Source: Anthera Pharmaceuticals Inc) Positive trends from BRIGHT-SC proof-of-concept study - study to continue SOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016 First patients screened in Phase 3 CHABLIS 7.5 study of blisibimod in seropositive lupus patients CHABLIS-SC1 results to be reported in the third quarter. Recent DSMB review found no safety issues HAYWARD, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced results from interim analysis of the Phase 2 BRIGHT-SC proof-of-concept study in 57 patients with biopsy-proven IgA Nephropathy. Additionally, Anthera announced that its Phase 3 SOLUTION...